5,057 results on '"Martinelli, Giovanni"'
Search Results
352. Poster: MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma
353. Poster: MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment
354. Safety of FLT3 inhibitors in patients with acute myeloid leukemia
355. Heterogeneous self-tracked health and fitness data integration and sharing according to a linked open data approach
356. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
357. Review report by Giovanni Martinelli about nhess-2020-369 by Gattuso et al.2021
358. Lineage‐specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture
359. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors
360. Abstract 2776: Sequential immunohistochemistry and computational image analysis for a deeper characterization of tumor-infiltrating myeloid cells
361. Abstract 2907: A metaproteomic approach to study the host-microbiota interaction in cancer tissue
362. Abstract 541: Liquid biopsy for molecular characterization and monitoring in patients with metastatic colorectal cancer
363. Abstract 709: Estrogen and androgen receptor inhibitors: Unexpected allies in the fight against COVID-19
364. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
365. Evidence of late-Holocene mud-volcanic eruptions in the Modena foothills (northern Italy)
366. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
367. Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
368. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34− cell population with intrinsic resistance to imatinib
369. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
370. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
371. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)
372. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
373. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up
374. Germline polymorphisms and survival of lung adenocarcinoma patients: A genome-wide study in two European patient series
375. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi
376. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
377. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
378. New targets for Ph+ leukaemia therapy
379. The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia
380. Additional file 2 of Clinical research activities during COVID-19: the point of view of a promoter of academic clinical trials
381. Additional file 1 of Clinical research activities during COVID-19: the point of view of a promoter of academic clinical trials
382. Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation
383. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
384. An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study (Preprint)
385. Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient
386. Tamoxifen protects breast cancer patients from COVID-19: first evidence from real world data
387. Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia
388. Reliability of Body Temperature Measurements Obtained with Contactless Infrared Point Thermometers Commonly Used during the COVID-19 Pandemic
389. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
390. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer
391. Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
392. Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.
393. Exposure–response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer
394. Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
395. Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer
396. Immunotherapy in Acute Myeloid Leukemia: Where We Stand
397. Exploring the ATR-CHK1 Pathway in the Response of Doxorubicin-induced DNA Damages in Acute Lymphoblastic Leukemia Cells
398. Clinical research activities during COVID-19: the point of view of a promoter of academic clinical trials
399. The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia
400. Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.